Review





Similar Products

95
Miltenyi Biotec tim3 apc
Tim3 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tim3 apc/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
tim3 apc - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

95
Miltenyi Biotec cd366 tim3 rea635 apc human miltenyi cd366
Cd366 Tim3 Rea635 Apc Human Miltenyi Cd366, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd366 tim3 rea635 apc human miltenyi cd366/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
cd366 tim3 rea635 apc human miltenyi cd366 - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

90
Thermo Fisher anti- tim3 apc (rmt3- 23, 1:100)
Anti Tim3 Apc (Rmt3 23, 1:100), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti- tim3 apc (rmt3- 23, 1:100)/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
anti- tim3 apc (rmt3- 23, 1:100) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

94
Miltenyi Biotec miltenyi biotec 130 113 353 tim3 apc
Miltenyi Biotec 130 113 353 Tim3 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/miltenyi biotec 130 113 353 tim3 apc/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
miltenyi biotec 130 113 353 tim3 apc - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

90
Becton Dickinson anti-mouse tim3 apc 5d12
CXCR6 and CXCL16 expression in human and murine tumors tracks with dysfunctional T cells and myeloid cells, respectively (A) Mean expression (color bar) and fraction of expressing cells (dot size) for CXCR6 and CXCL16 (columns) across cell types (rows) in different human tumor studies (panels). (B) GSEA plots obtained for the KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION gene set when compared against the ranking of genes based on their co-expression with CXCL16 in macrophages in the indicated tumors. (C) Frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of total (top) or Ova-Dextramer + (bottom) CD8 + TILs harvested from B16F10, B16Ova, or Mc38Ova hi tumors (top: B16F10, n = 8, 2 experiments combined. B16Ova, n = 10, 2 experiments combined. Mc38Ova hi , n = 9, 2 experiments combined. Bottom: B16Ova, n = 3, 1 experiment. Mc38Ova hi , n = 15, 2 experiments combined). (D) Representative distributions of expression levels (x axis, fluorescence intensity) in CXCR6 + and CXCR6 − CD8 + TILs from B16Ova tumors ( n = 4, 1 experiment). (E) Representative distributions of CXCL16 surface (top) or intracellular (bottom) expression (x axis, fluorescence intensity) in myeloid cells from Mc38Ova hi , B16Ova, or B16F10 tumors ( n = 4 per tumor, 1 experiment). (F) Left: B16Ova tumor area (y axis, mean ± SEM) of early-stage or late-stage tumors. Middle: frequency (y axis, mean ± SEM) of PD1- and <t>TIM3-expressing</t> CD8 + TILs (x axis) in early- or late-stage tumors. Right: frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of CD8 + TILs from early- or late-stage B16Ova tumors ( n = 12, 2 experiments combined). Statistical significance was determined by Student’s unpaired t test (C, F). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
Anti Mouse Tim3 Apc 5d12, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-mouse tim3 apc 5d12/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
anti-mouse tim3 apc 5d12 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Thermo Fisher anti-tim3 f38-2e2 pe or apc
CXCR6 and CXCL16 expression in human and murine tumors tracks with dysfunctional T cells and myeloid cells, respectively (A) Mean expression (color bar) and fraction of expressing cells (dot size) for CXCR6 and CXCL16 (columns) across cell types (rows) in different human tumor studies (panels). (B) GSEA plots obtained for the KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION gene set when compared against the ranking of genes based on their co-expression with CXCL16 in macrophages in the indicated tumors. (C) Frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of total (top) or Ova-Dextramer + (bottom) CD8 + TILs harvested from B16F10, B16Ova, or Mc38Ova hi tumors (top: B16F10, n = 8, 2 experiments combined. B16Ova, n = 10, 2 experiments combined. Mc38Ova hi , n = 9, 2 experiments combined. Bottom: B16Ova, n = 3, 1 experiment. Mc38Ova hi , n = 15, 2 experiments combined). (D) Representative distributions of expression levels (x axis, fluorescence intensity) in CXCR6 + and CXCR6 − CD8 + TILs from B16Ova tumors ( n = 4, 1 experiment). (E) Representative distributions of CXCL16 surface (top) or intracellular (bottom) expression (x axis, fluorescence intensity) in myeloid cells from Mc38Ova hi , B16Ova, or B16F10 tumors ( n = 4 per tumor, 1 experiment). (F) Left: B16Ova tumor area (y axis, mean ± SEM) of early-stage or late-stage tumors. Middle: frequency (y axis, mean ± SEM) of PD1- and <t>TIM3-expressing</t> CD8 + TILs (x axis) in early- or late-stage tumors. Right: frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of CD8 + TILs from early- or late-stage B16Ova tumors ( n = 12, 2 experiments combined). Statistical significance was determined by Student’s unpaired t test (C, F). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
Anti Tim3 F38 2e2 Pe Or Apc, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-tim3 f38-2e2 pe or apc/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
anti-tim3 f38-2e2 pe or apc - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

93
Miltenyi Biotec apc anti human tim3
CXCR6 and CXCL16 expression in human and murine tumors tracks with dysfunctional T cells and myeloid cells, respectively (A) Mean expression (color bar) and fraction of expressing cells (dot size) for CXCR6 and CXCL16 (columns) across cell types (rows) in different human tumor studies (panels). (B) GSEA plots obtained for the KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION gene set when compared against the ranking of genes based on their co-expression with CXCL16 in macrophages in the indicated tumors. (C) Frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of total (top) or Ova-Dextramer + (bottom) CD8 + TILs harvested from B16F10, B16Ova, or Mc38Ova hi tumors (top: B16F10, n = 8, 2 experiments combined. B16Ova, n = 10, 2 experiments combined. Mc38Ova hi , n = 9, 2 experiments combined. Bottom: B16Ova, n = 3, 1 experiment. Mc38Ova hi , n = 15, 2 experiments combined). (D) Representative distributions of expression levels (x axis, fluorescence intensity) in CXCR6 + and CXCR6 − CD8 + TILs from B16Ova tumors ( n = 4, 1 experiment). (E) Representative distributions of CXCL16 surface (top) or intracellular (bottom) expression (x axis, fluorescence intensity) in myeloid cells from Mc38Ova hi , B16Ova, or B16F10 tumors ( n = 4 per tumor, 1 experiment). (F) Left: B16Ova tumor area (y axis, mean ± SEM) of early-stage or late-stage tumors. Middle: frequency (y axis, mean ± SEM) of PD1- and <t>TIM3-expressing</t> CD8 + TILs (x axis) in early- or late-stage tumors. Right: frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of CD8 + TILs from early- or late-stage B16Ova tumors ( n = 12, 2 experiments combined). Statistical significance was determined by Student’s unpaired t test (C, F). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
Apc Anti Human Tim3, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apc anti human tim3/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
apc anti human tim3 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

90
Thermo Fisher anti-tim3-apc
CXCR6 and CXCL16 expression in human and murine tumors tracks with dysfunctional T cells and myeloid cells, respectively (A) Mean expression (color bar) and fraction of expressing cells (dot size) for CXCR6 and CXCL16 (columns) across cell types (rows) in different human tumor studies (panels). (B) GSEA plots obtained for the KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION gene set when compared against the ranking of genes based on their co-expression with CXCL16 in macrophages in the indicated tumors. (C) Frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of total (top) or Ova-Dextramer + (bottom) CD8 + TILs harvested from B16F10, B16Ova, or Mc38Ova hi tumors (top: B16F10, n = 8, 2 experiments combined. B16Ova, n = 10, 2 experiments combined. Mc38Ova hi , n = 9, 2 experiments combined. Bottom: B16Ova, n = 3, 1 experiment. Mc38Ova hi , n = 15, 2 experiments combined). (D) Representative distributions of expression levels (x axis, fluorescence intensity) in CXCR6 + and CXCR6 − CD8 + TILs from B16Ova tumors ( n = 4, 1 experiment). (E) Representative distributions of CXCL16 surface (top) or intracellular (bottom) expression (x axis, fluorescence intensity) in myeloid cells from Mc38Ova hi , B16Ova, or B16F10 tumors ( n = 4 per tumor, 1 experiment). (F) Left: B16Ova tumor area (y axis, mean ± SEM) of early-stage or late-stage tumors. Middle: frequency (y axis, mean ± SEM) of PD1- and <t>TIM3-expressing</t> CD8 + TILs (x axis) in early- or late-stage tumors. Right: frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of CD8 + TILs from early- or late-stage B16Ova tumors ( n = 12, 2 experiments combined). Statistical significance was determined by Student’s unpaired t test (C, F). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
Anti Tim3 Apc, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-tim3-apc/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
anti-tim3-apc - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

93
Miltenyi Biotec anti human tim3 apc
CXCR6 and CXCL16 expression in human and murine tumors tracks with dysfunctional T cells and myeloid cells, respectively (A) Mean expression (color bar) and fraction of expressing cells (dot size) for CXCR6 and CXCL16 (columns) across cell types (rows) in different human tumor studies (panels). (B) GSEA plots obtained for the KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION gene set when compared against the ranking of genes based on their co-expression with CXCL16 in macrophages in the indicated tumors. (C) Frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of total (top) or Ova-Dextramer + (bottom) CD8 + TILs harvested from B16F10, B16Ova, or Mc38Ova hi tumors (top: B16F10, n = 8, 2 experiments combined. B16Ova, n = 10, 2 experiments combined. Mc38Ova hi , n = 9, 2 experiments combined. Bottom: B16Ova, n = 3, 1 experiment. Mc38Ova hi , n = 15, 2 experiments combined). (D) Representative distributions of expression levels (x axis, fluorescence intensity) in CXCR6 + and CXCR6 − CD8 + TILs from B16Ova tumors ( n = 4, 1 experiment). (E) Representative distributions of CXCL16 surface (top) or intracellular (bottom) expression (x axis, fluorescence intensity) in myeloid cells from Mc38Ova hi , B16Ova, or B16F10 tumors ( n = 4 per tumor, 1 experiment). (F) Left: B16Ova tumor area (y axis, mean ± SEM) of early-stage or late-stage tumors. Middle: frequency (y axis, mean ± SEM) of PD1- and <t>TIM3-expressing</t> CD8 + TILs (x axis) in early- or late-stage tumors. Right: frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of CD8 + TILs from early- or late-stage B16Ova tumors ( n = 12, 2 experiments combined). Statistical significance was determined by Student’s unpaired t test (C, F). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
Anti Human Tim3 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human tim3 apc/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
anti human tim3 apc - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

Image Search Results


CXCR6 and CXCL16 expression in human and murine tumors tracks with dysfunctional T cells and myeloid cells, respectively (A) Mean expression (color bar) and fraction of expressing cells (dot size) for CXCR6 and CXCL16 (columns) across cell types (rows) in different human tumor studies (panels). (B) GSEA plots obtained for the KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION gene set when compared against the ranking of genes based on their co-expression with CXCL16 in macrophages in the indicated tumors. (C) Frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of total (top) or Ova-Dextramer + (bottom) CD8 + TILs harvested from B16F10, B16Ova, or Mc38Ova hi tumors (top: B16F10, n = 8, 2 experiments combined. B16Ova, n = 10, 2 experiments combined. Mc38Ova hi , n = 9, 2 experiments combined. Bottom: B16Ova, n = 3, 1 experiment. Mc38Ova hi , n = 15, 2 experiments combined). (D) Representative distributions of expression levels (x axis, fluorescence intensity) in CXCR6 + and CXCR6 − CD8 + TILs from B16Ova tumors ( n = 4, 1 experiment). (E) Representative distributions of CXCL16 surface (top) or intracellular (bottom) expression (x axis, fluorescence intensity) in myeloid cells from Mc38Ova hi , B16Ova, or B16F10 tumors ( n = 4 per tumor, 1 experiment). (F) Left: B16Ova tumor area (y axis, mean ± SEM) of early-stage or late-stage tumors. Middle: frequency (y axis, mean ± SEM) of PD1- and TIM3-expressing CD8 + TILs (x axis) in early- or late-stage tumors. Right: frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of CD8 + TILs from early- or late-stage B16Ova tumors ( n = 12, 2 experiments combined). Statistical significance was determined by Student’s unpaired t test (C, F). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Journal: Cell Reports Medicine

Article Title: Pan-cancer mapping of single CD8 + T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity

doi: 10.1016/j.xcrm.2024.101640

Figure Lengend Snippet: CXCR6 and CXCL16 expression in human and murine tumors tracks with dysfunctional T cells and myeloid cells, respectively (A) Mean expression (color bar) and fraction of expressing cells (dot size) for CXCR6 and CXCL16 (columns) across cell types (rows) in different human tumor studies (panels). (B) GSEA plots obtained for the KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION gene set when compared against the ranking of genes based on their co-expression with CXCL16 in macrophages in the indicated tumors. (C) Frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of total (top) or Ova-Dextramer + (bottom) CD8 + TILs harvested from B16F10, B16Ova, or Mc38Ova hi tumors (top: B16F10, n = 8, 2 experiments combined. B16Ova, n = 10, 2 experiments combined. Mc38Ova hi , n = 9, 2 experiments combined. Bottom: B16Ova, n = 3, 1 experiment. Mc38Ova hi , n = 15, 2 experiments combined). (D) Representative distributions of expression levels (x axis, fluorescence intensity) in CXCR6 + and CXCR6 − CD8 + TILs from B16Ova tumors ( n = 4, 1 experiment). (E) Representative distributions of CXCL16 surface (top) or intracellular (bottom) expression (x axis, fluorescence intensity) in myeloid cells from Mc38Ova hi , B16Ova, or B16F10 tumors ( n = 4 per tumor, 1 experiment). (F) Left: B16Ova tumor area (y axis, mean ± SEM) of early-stage or late-stage tumors. Middle: frequency (y axis, mean ± SEM) of PD1- and TIM3-expressing CD8 + TILs (x axis) in early- or late-stage tumors. Right: frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of CD8 + TILs from early- or late-stage B16Ova tumors ( n = 12, 2 experiments combined). Statistical significance was determined by Student’s unpaired t test (C, F). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: Anti-Mouse Tim3 APC Clone 5D12 , BD , Cat:# 567164 RRID: AB_2916481.

Techniques: Expressing, Fluorescence

CXCR6 expression increases upon ICB and is repressed by TCF1 (A and B) Left: tumor area (y axis, mean ± SEM) over time (x axis) of Mc38Ova hi (A) or B16Ova (B) implanted in wild-type (WT) mice and treated with anti-PD1 (A), anti-PD-L1 + anti-TIM3 (B), or isotype control. Right: frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of CD8 + TILs harvested from tumors treated as above (A: n = 4–6 per group, 1 experiment. B: n = 3–4 per group, 1 experiment). (C) Expression (row-normalized TPM, color bar) of top differentially expressed genes (rows) between WT OTI (E8i-Cre - , Tcf7 FL/FL ) and Tcf7 cKO OTI (E8i-Cre + , Tcf7 FL/FL ) cells at different time points after T cell activation (columns) ( n = 3, 1 experiment). (D) Mean expression (color bar) and fraction of expressing cells (dot size) of key genes (rows) in different CD8 + T cell clusters (columns) as determined by scRNA-seq of cells from B16Ova tumors implanted in WT or Tcf7 cKO mice ( n = 3 per group combined, 1 experiment). (E) Frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of CD8 + TILs from B16Ova tumors from WT (black) or Tcf7 cKO (green) mice ( n = 3–7 per group, representative of 2 experiments). (F) Percent input (y axis, mean ± SEM) following chromatin immunoprecipitation (ChIP) PCR of the Cxcr6 locus with anti-TCF1 or rabbit IgG control antibodies (x axis) in WT or Tcf7 cKO CD8 + T cells ( n = 8, 5 experiments combined). (G–I) Luciferase activity (RLU, relative light unit, y axis, mean ± SEM) in HEK293T cells transfected with Cxcr6 locus-containing pGL4.10 luciferase reporters together with either empty vector (control) or vectors encoding the indicated transcription factors (x axis). Firefly luciferase activity is presented relative to constitutive Renilla luciferase activity ( n = 3, representative of 2 experiments). Statistical significance was determined by linear mixed model (A left, B left), Student’s unpaired t test (A right, B right, E, F comparing WT to Tcf7 cKO anti-TCF1 samples), Student’s paired t test (F comparing WT samples), or one-way ANOVA with Tukey’s multiple comparisons test (G, H, I). NS = not significant, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Journal: Cell Reports Medicine

Article Title: Pan-cancer mapping of single CD8 + T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity

doi: 10.1016/j.xcrm.2024.101640

Figure Lengend Snippet: CXCR6 expression increases upon ICB and is repressed by TCF1 (A and B) Left: tumor area (y axis, mean ± SEM) over time (x axis) of Mc38Ova hi (A) or B16Ova (B) implanted in wild-type (WT) mice and treated with anti-PD1 (A), anti-PD-L1 + anti-TIM3 (B), or isotype control. Right: frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of CD8 + TILs harvested from tumors treated as above (A: n = 4–6 per group, 1 experiment. B: n = 3–4 per group, 1 experiment). (C) Expression (row-normalized TPM, color bar) of top differentially expressed genes (rows) between WT OTI (E8i-Cre - , Tcf7 FL/FL ) and Tcf7 cKO OTI (E8i-Cre + , Tcf7 FL/FL ) cells at different time points after T cell activation (columns) ( n = 3, 1 experiment). (D) Mean expression (color bar) and fraction of expressing cells (dot size) of key genes (rows) in different CD8 + T cell clusters (columns) as determined by scRNA-seq of cells from B16Ova tumors implanted in WT or Tcf7 cKO mice ( n = 3 per group combined, 1 experiment). (E) Frequency of CXCR6 + cells (y axis, mean ± SEM) in the indicated subsets (x axis) of CD8 + TILs from B16Ova tumors from WT (black) or Tcf7 cKO (green) mice ( n = 3–7 per group, representative of 2 experiments). (F) Percent input (y axis, mean ± SEM) following chromatin immunoprecipitation (ChIP) PCR of the Cxcr6 locus with anti-TCF1 or rabbit IgG control antibodies (x axis) in WT or Tcf7 cKO CD8 + T cells ( n = 8, 5 experiments combined). (G–I) Luciferase activity (RLU, relative light unit, y axis, mean ± SEM) in HEK293T cells transfected with Cxcr6 locus-containing pGL4.10 luciferase reporters together with either empty vector (control) or vectors encoding the indicated transcription factors (x axis). Firefly luciferase activity is presented relative to constitutive Renilla luciferase activity ( n = 3, representative of 2 experiments). Statistical significance was determined by linear mixed model (A left, B left), Student’s unpaired t test (A right, B right, E, F comparing WT to Tcf7 cKO anti-TCF1 samples), Student’s paired t test (F comparing WT samples), or one-way ANOVA with Tukey’s multiple comparisons test (G, H, I). NS = not significant, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: Anti-Mouse Tim3 APC Clone 5D12 , BD , Cat:# 567164 RRID: AB_2916481.

Techniques: Expressing, Control, Activation Assay, Chromatin Immunoprecipitation, Luciferase, Activity Assay, Transfection, Plasmid Preparation

Journal: Cell Reports Medicine

Article Title: Pan-cancer mapping of single CD8 + T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity

doi: 10.1016/j.xcrm.2024.101640

Figure Lengend Snippet:

Article Snippet: Anti-Mouse Tim3 APC Clone 5D12 , BD , Cat:# 567164 RRID: AB_2916481.

Techniques: Virus, Recombinant, Purification, SYBR Green Assay, Staining, Reporter Assay, In Vitro, Activation Assay, Generated, Luciferase, Plasmid Preparation, Sequencing, Software, CRISPR